Moderna, Inc.
Market Data Current As Of: September 12, 2026
Related Competitor Intelligence
Compare market positioning with top industry peers
Explore Moderna
Core profile pages, annual revenue records, and related research hubs for this company.
Moderna, Inc.
Compare market positioning with top industry peers
Explore Moderna
Core profile pages, annual revenue records, and related research hubs for this company.
Financial Performance
Revenue
$1.94B
Market Cap
$38.5B
Employees
5,600
Moderna is fighting a desperate, critical battle to prove its proprietary mRNA platform can actually cure diseases beyond the COVID-19 pandemic. Under CEO Stéphane Bancel, the biotech pioneer generated exactly $4.1 billion in revenue and maintains a speculative $38.5 billion market cap with exactly 5600 employees. The financial narrative in 2026 is entirely defined by cash burn and critical clinical readouts; desperately trying to escape a total collapse in vaccine revenues, Moderna extracts remaining capital to furiously push complex, expensive personalized cancer vaccines (PCV) and RSV shots through late-stage trials.
Revenue Trend Analysis
YoY Change
-39.9%
2-Year CAGR
-46.7%
Peak Year
2023
Trend
Declining Trend
Moderna, Inc. has reported revenue across 3 fiscal years, compounding at -46.7% annually over 2 years. The most recent year saw a 39.9% decline versus the prior year. Revenue peaked in 2023 at $6.8B. Out of 2 reported periods, 0 showed growth and 2 showed a decline.
| Fiscal Year | Revenue | Net Income | YoY Change |
|---|---|---|---|
| FY2025 | $1.9B | N/A | -39.9% |
| FY2024 | $3.2B | N/A | -52.7% |
| FY2023 | $6.8B | N/A | — |
Source: SEC EDGAR filings, annual earnings releases, and verified financial disclosures.
Click any row to see year details.
Moderna, Inc. reported approximately $4.1B in fiscal year 2025 with a team of 5,600 employees worldwide.
Moderna, Inc. strategically balances reinvestment into core R&D with operational cost discipline, focusing on workflow automation to expand operating margins in 2026.
Financial performance in Biotechnology, Pharmaceuticals, Vaccines, and mRNA Medicines is driven by steady cash generation and pricing power, enabling Moderna, Inc. to reinvest in high-return strategic initiatives.
Using these figures? Please credit CorpDigest with a link.
CorpDigest. "Moderna, Inc. Revenue & Financials." CorpDigest, https://corpdigest.com/company/moderna/financials.<div style="font-family:system-ui,sans-serif;font-size:14px;line-height:1.5;border:1px solid #e2e8f0;border-radius:8px;padding:12px 16px;max-width:520px"><strong>Moderna, Inc. reported $2B in revenue (FY2025).</strong><br>Source: <a href="https://corpdigest.com/company/moderna/financials" target="_blank" rel="noopener">CorpDigest — Moderna, Inc. financials</a></div>